Buy Cablivi (caplacizumab)

What is Cablivi (caplacizumab)?

Buy Cablivi (caplacizumab). Cablivi (caplacizumab) is a new medicine for adults with a rare blood disorder called acquired thrombotic thrombocytopenic purpura (aTTP). It comes in powder or solution form. It’s used with plasma exchange and other treatments.

How does Cablivi (caplacizumab) work?

aTTP is a rare disorder where blood clots form in small blood vessels. This causes low platelet count, bleeding under the skin, and low red blood cell count. It also leads to haemolytic anaemia.

In aTTP, the body makes too much of a protein called von Willebrand factor (vWF). This protein makes platelets stick together and form clots. Cablivi’s active ingredient, caplacizumab, is an antibody that blocks vWF’s action. It stops platelets from sticking and forming clots.

Where has Cablivi (caplacizumab) been approved?

Cablivi (caplacizumab) has been approved by:

• Food and Drug Administration (FDA), USA, February 6, 2019
• European Medical Agency (EMA), European Union, August 30, 2018
• Therapeutic Goods Administration (TGA), Australia, February 5, 2020

for treating patients with acquired thrombotic thrombocytopenic purpura (aTTP).

The European Medicines Agency, Europe (2009); the Food and Drug Administration, United States (2009); Swissmedic, Switzerland (2017); Japanese Pharmaceuticals and Medical Devices Agency, Japan (2018) granted caplacizumab orphan drug designation. Orphan drug designation helps speed up the development of medicines for rare conditions.

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

 

How is Cablivi (caplacizumab) taken?

The standard dosage recommended by:

• The EMA:
  • First dose: intravenous injection of 10 mg of caplacizumab prior to plasma exchange
  • Subsequent doses: daily subcutaneous administration of 10 mg of caplacizumab after completion of each plasma exchange for the duration of daily plasma exchange treatment, followed by daily subcutaneous injection of 10 mg of caplacizumab for 30 days after stopping daily plasma exchange treatment.

• The FDA:
  • First day of treatment: 11 mg bolus intravenous injection at least 15 minutes prior to plasma exchange followed by an 11 mg subcutaneous injection after completion of plasma exchange on day 1.
  • Subsequent days of treatment during daily plasma exchange: 11 mg subcutaneous injection once daily following plasma exchange.
  • Treatment after plasma exchange period: 11 mg subcutaneous injection once daily continuing for 30 days following the last daily plasma exchange.

Warning: Treatment with Cablivi (caplacizumab) should be initiated and supervised by physicians experienced in the management of patients with thrombotic microangiopathies.

Complete information about Cablivi (caplacizumab) dosage and administration can be found in the official prescribing information listed in our resources section.

Note: Please consult with your treating doctor for personalised dosing and potential drug interactions.

Are there any known side effects or adverse reactions of Cablivi (caplacizumab)?

The most common side effects include:

• headache
• nosebleed
• gingival bleeding
• urticaria
• fatigue.

Cablivi (caplacizumab) can be fatal for a foetus. It’s important to avoid pregnancies and breastfeeding.

For a full list of side effects and adverse reactions, see the official prescribing information.

Buy Andexxa (recombinant)